Surrozen Inc
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which co… Read more
Surrozen Inc (SRZN) - Total Liabilities
Latest total liabilities as of September 2025: $117.56 Million USD
Based on the latest financial reports, Surrozen Inc (SRZN) has total liabilities worth $117.56 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Surrozen Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how Surrozen Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Surrozen Inc Competitors by Total Liabilities
The table below lists competitors of Surrozen Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dicot AB
ST:DICOT
|
Sweden | Skr12.10 Million |
|
SKY Metals Ltd
AU:SKY
|
Australia | AU$1.48 Million |
|
Bonraybio Co., Ltd.
TW:6955
|
Taiwan | NT$50.28 Million |
|
Sriracha Construction Public Company Limited
BK:SRICHA
|
Thailand | ฿1.58 Billion |
|
Me2on Co. Ltd
KQ:201490
|
Korea | ₩52.04 Billion |
|
KPX Chemical
KO:025000
|
Korea | ₩195.44 Billion |
|
Jiangsu Recbio Technology Co., Ltd.
F:G93
|
Germany | €1.37 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Surrozen Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -5.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Surrozen Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Surrozen Inc (2019–2024)
The table below shows the annual total liabilities of Surrozen Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $69.85 Million | +757.54% |
| 2023-12-31 | $8.14 Million | -39.37% |
| 2022-12-31 | $13.43 Million | -51.10% |
| 2021-12-31 | $27.47 Million | +86.05% |
| 2020-12-31 | $14.77 Million | +12.73% |
| 2019-12-31 | $13.10 Million | -- |